Announced
Synopsis
ARCHIMED, a private equity healthcare specialist, agreed to acquire a majority stake in Magellan Biologics & Consulting, a provider of transient protein expression products, consulting, and small volume protein production, and ExcellGene, a company which is providing services and production in the field of recombinant biologics made with animal cells in bioreactors, such as proteins and virus vectors. Financial terms were not disclosed.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite